Xing Wang1, Yang Wang2, Shaolei Li1, Bin Dong3, Qingfeng Zheng1, Shi Yan1, Yuanyuan Ma1, Jianzhi Zhang1, Jian Fang2, Nan Wu1, Huijuan Wu4, Yue Yang1. 1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Surgery, Peking University Cancer Hospital & Institute Beijing, China. 2. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Respiratory Medicine, Peking University Cancer Hospital & Institute Beijing, China. 3. Department of Pathology, Peking University Cancer Hospital & Institute Beijing, China. 4. Beijing Center for Physical and Chemical Analysis Beijing, China.
Abstract
BACKGROUND: This study aimed to investigate the clinical significance of the combination of maspin and vascular endothelial growth factor (VEGF)-C expression in the prognosis of non-small cell lung cancer (NSCLC). METHODS: Immunohistochemistry was performed to assay the expression of maspin and VEGF-C in primary tumor tissues, metastatic, and non-metastatic lymph nodes in 98 NSCLC patients. Survival analysis was determined by Kaplan-Meier curves. RESULTS: The positive expression rate of maspin was 26.5% (26/98) in NSCLC primary tumor tissues, significantly associated with histological type (P = 0.005) and the absence of nodal metastasis (P < 0.001). The expression of maspin in primary tumor tissues was stronger than metastatic lymph nodes of the N1 group (P = 0.048), while the metastatic lymph nodes of the N1 group had a stronger maspin expression than the N2 group (P = 0.008). In survival analysis, a positive expression of maspin of the N1 lymph node was also found to be an independent positive prognostic factor in overall survival (P = 0.003). We also found that decreased maspin combined with elevated VEGF-C is associated with a poor prognosis for disease-free survival (P = 0.019). CONCLUSION: Our results suggest that positive expression of maspin might significantly inhibit nodal metastasis in NSCLC. Decreased maspin combined with elevated VEGF-C might be associated with a poor prognosis in NSCLC.
BACKGROUND: This study aimed to investigate the clinical significance of the combination of maspin and vascular endothelial growth factor (VEGF)-C expression in the prognosis of non-small cell lung cancer (NSCLC). METHODS: Immunohistochemistry was performed to assay the expression of maspin and VEGF-C in primary tumor tissues, metastatic, and non-metastatic lymph nodes in 98 NSCLCpatients. Survival analysis was determined by Kaplan-Meier curves. RESULTS: The positive expression rate of maspin was 26.5% (26/98) in NSCLC primary tumor tissues, significantly associated with histological type (P = 0.005) and the absence of nodal metastasis (P < 0.001). The expression of maspin in primary tumor tissues was stronger than metastatic lymph nodes of the N1 group (P = 0.048), while the metastatic lymph nodes of the N1 group had a stronger maspin expression than the N2 group (P = 0.008). In survival analysis, a positive expression of maspin of the N1 lymph node was also found to be an independent positive prognostic factor in overall survival (P = 0.003). We also found that decreased maspin combined with elevated VEGF-C is associated with a poor prognosis for disease-free survival (P = 0.019). CONCLUSION: Our results suggest that positive expression of maspin might significantly inhibit nodal metastasis in NSCLC. Decreased maspin combined with elevated VEGF-C might be associated with a poor prognosis in NSCLC.
Authors: Anil K Sood; Mavis S Fletcher; Lynn M Gruman; Jeremy E Coffin; Sarvenaz Jabbari; Zhila Khalkhali-Ellis; Nancy Arbour; Elisabeth A Seftor; Mary J C Hendrix Journal: Clin Cancer Res Date: 2002-09 Impact factor: 12.531
Authors: Z Zou; A Anisowicz; M J Hendrix; A Thor; M Neveu; S Sheng; K Rafidi; E Seftor; R Sager Journal: Science Date: 1994-01-28 Impact factor: 47.728
Authors: Eric Vallières; Frances A Shepherd; John Crowley; Paul Van Houtte; Pieter E Postmus; Desmond Carney; Kari Chansky; Zeba Shaikh; Peter Goldstraw Journal: J Thorac Oncol Date: 2009-09 Impact factor: 15.609